[go: up one dir, main page]

PE20200924A1 - Compuestos de bisamida sustituida que activan el sarcomero cardiaco - Google Patents

Compuestos de bisamida sustituida que activan el sarcomero cardiaco

Info

Publication number
PE20200924A1
PE20200924A1 PE2020000339A PE2020000339A PE20200924A1 PE 20200924 A1 PE20200924 A1 PE 20200924A1 PE 2020000339 A PE2020000339 A PE 2020000339A PE 2020000339 A PE2020000339 A PE 2020000339A PE 20200924 A1 PE20200924 A1 PE 20200924A1
Authority
PE
Peru
Prior art keywords
substituted
activate
compounds
prolinamide
azetidinyl
Prior art date
Application number
PE2020000339A
Other languages
English (en)
Inventor
Luke Ashcraft
Justin Malinowski
David Moebius
Bradley P Morgan
Joshua Payette
Antonio Romero
Jean David St Jr
Richard Vargas
John Yeoman
Hanmo Zhang
Alan Cheng
Alessandro Boezio
Lopez De Turiso Felix Gonzalez
Michael Garrett Johnson
John Butler
Aroop Chandra
Chihyuan Chuang
Scott E Collibee
Mikkel Debenedetto
Vincent Dimassa
Russell Graceffa
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of PE20200924A1 publication Critical patent/PE20200924A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BISAMIDA SUSTITUIDOS DE FORMULA (I) DONDE Q1, X1, X2, X3, X4, X5, R1, R1a, R13, R13a Y R14 SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 1-(3-((3-CIANO-1-AZETIDINIL)SULFONIL)BENZOIL)-N-((1R)-2-CICLOPROPIL-1-(4-(TRIFLUOROMETIL)FENIL)ETIL)-D-PROLINAMIDA; N-((R)-(4-CLORO-2-FLUOROFENIL)(CICLOPROPIL)METIL)-1-(((3S)-1-((3-CIANO-1-AZETIDINIL)SULFONIL)-3-PIPERIDINIL)CARBONIL)-D-PROLINAMIDA; 1-(3-((3-CIANO-1-AZETIDINIL)SULFONIL)BENZOIL)-N-((1R)-1-(4-(TRIFLUOROMETIL)FENIL)PROPIL)-D-PROLINAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL SARCOMERO CARDIACO SIENDO UTILES EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA CONGESTIVA.
PE2020000339A 2017-09-13 2018-09-13 Compuestos de bisamida sustituida que activan el sarcomero cardiaco PE20200924A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557846P 2017-09-13 2017-09-13
PCT/US2018/050793 WO2019055590A1 (en) 2017-09-13 2018-09-13 SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20200924A1 true PE20200924A1 (es) 2020-09-14

Family

ID=63794635

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000339A PE20200924A1 (es) 2017-09-13 2018-09-13 Compuestos de bisamida sustituida que activan el sarcomero cardiaco

Country Status (24)

Country Link
US (6) US10723720B2 (es)
EP (1) EP3681882A1 (es)
JP (1) JP7308816B2 (es)
KR (1) KR20200054237A (es)
CN (1) CN111601798B (es)
AR (1) AR112804A1 (es)
AU (1) AU2018332887B2 (es)
BR (1) BR112020004800A2 (es)
CA (1) CA3075669A1 (es)
CL (1) CL2020000610A1 (es)
CO (1) CO2020002745A2 (es)
CR (1) CR20200116A (es)
EA (1) EA202090688A1 (es)
IL (1) IL272573B2 (es)
JO (1) JOP20200059A1 (es)
MA (1) MA50173A (es)
MX (2) MX2020002696A (es)
PE (1) PE20200924A1 (es)
PH (1) PH12020500446A1 (es)
SA (1) SA520411524B1 (es)
SG (1) SG11202001377PA (es)
TW (1) TWI790281B (es)
UY (1) UY37879A (es)
WO (1) WO2019055590A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200924A1 (es) 2017-09-13 2020-09-14 Amgen Inc Compuestos de bisamida sustituida que activan el sarcomero cardiaco
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
SG11202010925UA (en) * 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
WO2020185983A1 (en) * 2019-03-12 2020-09-17 Amgen Inc. Polymorphs of a cardiac troponin activator
WO2020185982A1 (en) * 2019-03-12 2020-09-17 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
UY38794A (es) * 2019-07-23 2021-02-26 Bayer Ag Novedosos compuestos de heteroaril-triazol como plaguicidas
KR20220110529A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
AU2020396565C1 (en) 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
CR20220642A (es) * 2020-06-17 2023-02-15 Merck Sharp & Dohme Llc 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
US11814367B2 (en) 2021-03-15 2023-11-14 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
WO2023122325A2 (en) * 2021-12-23 2023-06-29 Regents Of The University Of Michigan Meta anilide compounds and methods for use of the same to treat diseases and disorders
WO2024073426A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-dihydroquinazolinone compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
US5952307A (en) 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
GB9708119D0 (en) 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
AU1082901A (en) 1999-10-18 2001-04-30 National Jewish Medical And Research Center Method for modulation of cell phenotype
US20020002171A1 (en) 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
EP1364019A2 (en) 2000-11-07 2003-11-26 Board of Regents, The University of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
ES2387909T3 (es) 2003-01-14 2012-10-03 Cytokinetics, Inc. Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
WO2004086865A1 (en) 2003-03-27 2004-10-14 Cytokinetics, Inc. Compounds, compositions and methods
WO2004094610A2 (en) 2003-04-21 2004-11-04 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
JP2005298628A (ja) 2004-04-09 2005-10-27 Sumitomo Chemical Co Ltd オレフィン重合触媒成分及びオレフィン重合体の製造方法
PL216049B1 (pl) 2004-06-17 2014-02-28 Cytokinetics Inc Pochodne mocznika, kompozycje zawierajace pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia niewydolnosci serca
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007089805A2 (en) 2006-01-31 2007-08-09 The General Hospital Corporation Anti-hypertrophic effects and inotropic effects of picot
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2014534206A (ja) 2011-10-17 2014-12-18 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
PH12017501279B1 (en) 2015-01-22 2023-06-16 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
WO2016210240A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
EP4265597A3 (en) 2017-06-30 2023-11-22 Amgen Inc. Synthesis of omecamtiv mecarbil
PE20200924A1 (es) 2017-09-13 2020-09-14 Amgen Inc Compuestos de bisamida sustituida que activan el sarcomero cardiaco
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
WO2020185982A1 (en) 2019-03-12 2020-09-17 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
WO2020185983A1 (en) 2019-03-12 2020-09-17 Amgen Inc. Polymorphs of a cardiac troponin activator

Also Published As

Publication number Publication date
US10899746B2 (en) 2021-01-26
US20240158372A1 (en) 2024-05-16
CL2020000610A1 (es) 2020-11-13
IL272573B2 (en) 2023-10-01
US20220281850A1 (en) 2022-09-08
CR20200116A (es) 2021-04-28
CA3075669A1 (en) 2019-03-21
US10723720B2 (en) 2020-07-28
CN111601798B (zh) 2023-08-11
US20200223830A1 (en) 2020-07-16
JOP20200059A1 (ar) 2020-03-12
EP3681882A1 (en) 2020-07-22
TW201920096A (zh) 2019-06-01
KR20200054237A (ko) 2020-05-19
MX2022014864A (es) 2022-12-15
JP7308816B2 (ja) 2023-07-14
US11299479B1 (en) 2022-04-12
US20190077793A1 (en) 2019-03-14
IL272573A (en) 2020-03-31
AU2018332887A1 (en) 2020-02-27
MA50173A (fr) 2020-07-29
WO2019055590A1 (en) 2019-03-21
US11254658B2 (en) 2022-02-22
IL272573B1 (en) 2023-06-01
US20200223829A1 (en) 2020-07-16
EA202090688A1 (ru) 2020-07-06
AR112804A1 (es) 2019-12-11
SG11202001377PA (en) 2020-03-30
US11780826B2 (en) 2023-10-10
BR112020004800A2 (pt) 2020-09-24
PH12020500446A1 (en) 2020-11-09
TWI790281B (zh) 2023-01-21
JP2020533347A (ja) 2020-11-19
MX2020002696A (es) 2020-09-25
CO2020002745A2 (es) 2020-06-19
UY37879A (es) 2019-03-29
SA520411524B1 (ar) 2024-03-14
AU2018332887B2 (en) 2022-12-08
CN111601798A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
PE20200924A1 (es) Compuestos de bisamida sustituida que activan el sarcomero cardiaco
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
PE20210129A1 (es) Compuestos de 4-azaindol
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CY1114242T1 (el) Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CO2017005790A2 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
PE20191108A1 (es) Inhibidores selectivos de jak1
CU20120015A7 (es) Piridina y pirazina como derivados de moduladores de la proteína kinasa
CL2019003857A1 (es) Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas.
PE20161432A1 (es) Compuestos y composiciones para inducir condrogenesis
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20161363A1 (es) Moduladores del receptor acoplado a la proteina g40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
MX2017015740A (es) Moduladores de ror gamma (ror?).